"10.1371_journal.pone.0021121","plos one","2011-07-06T00:00:00Z","Michael P Stany; Vinod Vathipadiekal; Laurent Ozbun; Rebecca L Stone; Samuel C Mok; Hui Xue; Takashi Kagami; Yuwei Wang; Jessica N McAlpine; David Bowtell; Peter W Gout; Dianne M Miller; C Blake Gilks; David G Huntsman; Susan L Ellard; Yu-Zhuo Wang; Pablo Vivas-Mejia; Gabriel Lopez-Berestein; Anil K Sood; Michael J Birrer","Walter Reed Army Medical Center, Washington D.C., United States of America; Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, and Harvard Medical School, Boston, Massachusetts, United States of America; Cell and Cancer Biology Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, United States of America; Department of Gynecologic Oncology, M. D. Anderson Cancer Center, Houston, Texas, United States of America; Brigham and Women's Hospital, Harvard School of Public Health, Boston, Massachusetts, United States of America; Living Tumor Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of British Columbia, Vancouver, British Columbia, Canada; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Pathology, Genetic Pathology Evaluation Centre, Vancouver General Hospital, Centre for Translation and Applied Genomics, British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada; Department of Medical Oncology, British Columbia Cancer Agency - Southern Interior, Kelowna, British Columbia, Canada; The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada; Department of Experimental Therapeutics, M. D. Anderson Cancer Center, Houston, Texas, United States of America; Department of Cancer Biology, M. D. Anderson Cancer Center, Houston, Texas, United States of America; Center for RNA Interference and Non-Coding RNA, M. D. Anderson Cancer Center, Texas, United States of America","Conceived and designed the experiments: SM AKS MJB. Analyzed the data: MPS VV LO DB MJB. Wrote the paper: SM DB AKS MJB. Performed the microarray experiments and in vitro experiments: MPS VV LO MJB. Performed siRNA in vivo experiments: RLS PV-M GL-B AKS. Performed sunitinib studies in patient-derived tumor tissue xenografts: HX TK YW JNM PWG DMM CBG DGH SLE Y-ZW. Provided tumor tissue samples: SM HX TK YW JNM PWG DMM CBG DGH SLE Y-ZW. Provided reagents/materials/analysis tools: SM AKS MJB. Prepared figures and drafted the manuscript: MPS VV MJB.","Pfizer Canada is a healthcare company. SLE and YZW received Investigator-initiated project funding from Pfizer Canada. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2011","07","Michael P Stany","MPS",20,TRUE,3,4,5,4,TRUE,TRUE,FALSE,0,NA,FALSE
